Featured Research

from universities, journals, and other organizations

Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma, study suggests

Date:
December 12, 2011
Source:
Queen's University
Summary:
New research demonstrates that patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.

New research led by the NCIC Clinical Trials Group (CTG) at Queen's University has proven patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.

"These results will influence current treatment practices and lead to more patients being treated with chemotherapy alone," says Dr. Ralph Meyer, professor of oncology at Queen's and director of the NCIC CTG. "This trial exemplifies the importance of academic groups conducting trials that assess long-term patient outcomes."

Previously, a patient diagnosed with Stage 1A or Stage 2A Hodgkin's lymphoma was treated with chemotherapy and extensive radiation. This combination often results in long term-complications from radiation exposure including heart conditions or subsequent cancers. This study proves chemotherapy alone increases survival rates in the early stages of the disease. The trial began in 1994 and has recently undergone its final analysis.

Today's practices incorporate reduced amounts of radiation as compared with those tested in the trial, but the results demonstrate chemotherapy alone will be a preferred option for many patients.

The study was made possible through NCIC CTG's grant funding from the Canadian Cancer Society Research Institute. The NCIC CTG led this trial in collaboration with the US-based Eastern Cooperative Oncology Group (ECOG). Both NCIC CTG and ECOG received grant funding support from the US National Cancer Institute.

The results were published on-line by the New England Journal of Medicine. Dr. Meyer presented the results December 12 at the American Society of Hematology conference in San Diego.


Story Source:

The above story is based on materials provided by Queen's University. Note: Materials may be edited for content and length.


Journal Reference:

  1. David J. Straus. Chemotherapy Alone for Early-Stage Hodgkin's Lymphoma. New England Journal of Medicine, 2011; 111211080015008 DOI: 10.1056/NEJMe1113291

Cite This Page:

Queen's University. "Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma, study suggests." ScienceDaily. ScienceDaily, 12 December 2011. <www.sciencedaily.com/releases/2011/12/111212124612.htm>.
Queen's University. (2011, December 12). Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/12/111212124612.htm
Queen's University. "Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/12/111212124612.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins